Patients with prostate cancer who undergo prostatectomy or radiotherapy have a higher risk of long-term complications than untreated patients with prostate cancer.

The FDA has approved obecabtagene autoleucel (Aucatzyl) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.